Celldex Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Celldex Therapeutics

06/05/2024 21:19

* Celldex Therapeutics Inc  CLDX.OQ  reported a quarterly
adjusted
loss of 56 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -62 cents.  The mean expectation of
five analysts for the quarter was for a loss of 69 cents per
share. Wall Street expected results to range from -75 cents
to -65 cents per share.
    * Revenue fell 83.9% to $156.00 thousand from a year ago;
analysts
expected $915.75 thousand. 
    * Celldex Therapeutics Inc's reported EPS for the quarter
was a
loss of 56 cents​.
    * The company reported a quarterly loss of $32.81 million.
    * Celldex Therapeutics Inc shares had risen by 1.4% this
quarter and gained 7.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Celldex
Therapeutics Inc is $77.00 
This summary was machine generated from LSEG data May 6 at 08:19
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.69          -0.56          Beat
 Dec. 31 2023      -0.74          -0.83          Missed
 Sep. 30 2023      -0.68          -0.81          Missed
 Jun. 30 2023      -0.67          -0.65          Beat